Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
Authors' conclusion
In the present study, we found that concomitant MTX had no effect on serum ETN concentration or on clinical response. In addition, a significant correlation was detected between ETN dose and ETN concentration.
Study context
- Population
- Juvenile idiopathic arthritis (JIA) patients treated with etanercept (ETN) monotherapy or combination therapy with DMARD, eight Finnish pediatric rheumatological centres
- Participants
- 180 patients
- Exposure
- Concomitant methotrexate (MTX) vs ETN monotherapy or synthetic disease modifying antirheumatic drug (sDMARDs) other than MTX
- MTXn = 97
- Non-MTXn = 83reference
- Outcome
- ETN serum trough levels in relation to ETN dose and concomitant MTX
Methodological detailsmulticentre, eight Finnish pediatric rheumatological centres, Trough blood samples collected right before the subsequent injection; free ETN measured from serum
- Multicentre
- Eight Finnish pediatric rheumatological centres
- Trough blood samples collected right before the subsequent injection; free ETN measured from serum
Main finding
As reported in the abstract
Correlation between ETN dose and serum drug level
MTX
0.35
r · 95% CI 0.14–0.52
Non-MTX
0.54
r · 95% CI 0.39–0.67
- ETN dose vs drug level, all patients (r)
- 0.45 (95% CI: 0.33-0.56)
- Dose and drug level correlated in both subgroups
- P = 0.030
Observational data: associations, not effects.
Original publication
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study. Pediatr Rheumatol Online J. Published 22 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →